Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Carlson, Noel G ^a,b,c,d   Rojas, Monica A ^b,c   Redd, Jonathan W ^b   Tang, Philip ^b   Wood, Blair ^b   Hill, Kenneth E ^b,c   Rose, John W ^b,c,d  

^a Education Clinical Center (GRECC) VASLCHCS   (United States)

^b VASLCHCS   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAY 10404; CAY 10452; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; KAINIC ACID; UNCLASSIFIED DRUG; GLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG ACTIVITY; EXCITOTOXICITY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PROMOTER REGION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; CARDIOVIRUS INFECTION; CONFOCAL MICROSCOPY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; MURINE ENCEPHALOMYELITIS VIRUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; SPINAL CORD;

ANIMALS; CARDIOVIRUS INFECTIONS; CELL DEATH; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DEMYELINATING DISEASES; FLUORESCENT ANTIBODY TECHNIQUE; GLUTAMIC ACID; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; ORGAN CULTURE TECHNIQUES; SPINAL CORD; THEILOVIRUS;

EID: 77950671614     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-25     Document Type: Article

References (56)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000, 343:938-952. 10.1056/NEJM200009283431307, 11006371.
2. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987, 14:255-261.
3. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955. 10.1056/NEJMra052130, 16510748.
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
5. Lipton HL. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun 1975, 115:1147-55.
6. Tsunoda I, Fujinami RS. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol 1996, 55:673-686. 10.1097/00005072-199606000-00001, 8642393.
7. Werner P, Pitt D, Raine CS. Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?. J Neural Transm Suppl 2000, 60:375-385.
8. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000, 6:62-66. 10.1038/71548, 10613825.
9. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000, 6:67-70. 10.1038/71555, 10613826.
10. Verkhratsky A, Steinhauser C. Ion channels in glial cells. Brain Res Rev 2000, 322:380-412.
11. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001, 24:224-230. 10.1016/S0166-2236(00)01746-X, 11250007.
12. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases cyclooxygenases-1 and -2. Adv Immunol 1996, 62:167-215. full_text, 8781269.
13. Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 2000, 293:417-425.
14. Carlson NG. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res 2003, 71:79-88. 10.1002/jnr.10465, 12478616.
15. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 17:2746-2755.
16. Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999, 19:1213-1219. 10.1097/00004647-199911000-00005, 10566967.
17. Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, Pasinetti GM. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999, 155:995-1004. 1866889, 10487857.
18. Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Shang Y, Shaffer A, Kaufmann WE, Worley PF, Isakson P, Markowska AL. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 2001, 21:8198-8209.
19. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 2001, 98:1294-1299. 10.1073/pnas.98.3.1294, 14748, 11158633.
20. Rose JW, Hill KE, Watt HE, Carlson NG. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol 2004, 149:40-49. 10.1016/j.jneuroim.2003.12.021, 15020063.
21. Carlson NG, Hill KE, Tsunoda I, Fujinami RS, Rose JW. The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol 2006, 174:21-31. 10.1016/j.jneuroim.2006.01.008, 16516308.
22. Tsoi VL, Hill KE, Carlson NG, Warner JE, Rose JW. Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 2006, 262:87-94.
23. Bruce-Keller AJ, Geddes JW, Knapp PE, McFall RW, Keller JN, Holtsberg FW, Parthasarathy S, Steiner SM, Mattson MP. Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. J Neuroimmunol 1999, 93:53-71. 10.1016/S0165-5728(98)00190-8, 10378869.
24. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol 1999, 163:3963-3968.
25. Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, Rose JW. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation 2009, 6:5. 10.1186/1742-2094-6-5, 2649915, 19222857.
26. Drachman DB, Frank BS, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic model of ALS. Ann Neurol 2002, 52:771-778. 10.1002/ana.10374, 12447931.
27. Chandross KJ, Cohen RI, Paras P, Gravel M, Braun PE, Hudson LD. Identification and characterization of early glial progenitors using a transgenic selection strategy. J Neurosci 1999, 192:759-774.
28. Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH, Langenbach R. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 2001, 98:1059-1064. 10.1073/pnas.031573498, 14708, 11158594.
29. Sanchez-Gomez MV, Alberdi E, Ibarretxe G, Torre I, Matute C. Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci 2003, 232:9519-9528.
30. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15:2057-2072. 10.1096/fj.01-0390rev, 11641233.
31. Balabanov R, Popko B. Myelin repair: developmental myelination redux?. Nature Neurosci 2005, 8:262-265. 10.1038/nn0305-262, 15746910.
32. Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJM, Stiles CD. BHLH transcription factor olig1 is required to repair demyelinated lesions in the CNS. Science 2004, 306:2111-2115. 10.1126/science.1103709, 15604411.
33. Leuschen MP, Filipi M, Healey K. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult Scler 2004, 10:636-642. 10.1191/1352458504ms1114oa, 15584488.
34. Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005, 64:1267-1269.
35. Wingerchuk DM, Rodriguez M. Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Arch Neurol 2006, 63:1005-1008. 10.1001/archneur.63.7.1005, 16831971.
36. Muthian G, Raikwar HP, Johnson C, Rajasingh J, Kalgutkar A, Marnett LJ, Bright JJ. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 2006, 261:73-85.
37. Miyamoto K, Miyake S, Mizuno M, Oka N, Kusunoki S, Yamamura T. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006, 129:1984-1992. 10.1093/brain/awl170, 16835249.
38. Reder AT, Thapar M, Supugay AM, Jensen MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 1994, 54:117-127. 10.1016/0165-5728(94)90238-0, 7523442.
39. Reder AT, Thapar M, Supugay AM, Jensen MA. Eicosenoids modify experimental allergic encephalomyelitis. Am J Ther 1995, 2:711-720. 10.1097/00045391-199509000-00020, 11854849.
40. Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, Ishii S, Shimizu T. Targeted lidpdomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proceedings Nat Acad Sci USA 2009, 106:21807-21812.
41. Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW. Inducible nitric oxide synthase in multiple sclerosis plaques: distribution, cellular expression, and pathologic consequences. J Neuroimmunol 2004, 151:171-179. 10.1016/j.jneuroim.2004.02.005, 15145615.
42. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998, 88:45-56. 10.1016/S0165-5728(98)00078-2, 9688323.
43. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001, 158:2057-2066. 1891989, 11395383.
44. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
45. Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 2004, 55:668-675. 10.1002/ana.20078, 15122707.
46. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006, 12:225-229. 10.1038/nm1362, 16432513.
47. Ahmad AS, Saleem S, Ahmad M, Dore S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 2006, 89:265-270. 10.1093/toxsci/kfj022, 16237196.
48. Gendron TF, Brunette E, Tauskela JS, Morley P. The dual role of prostaglandin E2 in excitotoxicity and preconditioning-induced neuroprotection. Eur J Pharm 2005, 517:12-27.
49. Dore S. GPCR antagonists as an alternative to COX-2 inhibitors: a case for PGE2 EP1 receptor. TRENDS in Pharm Sci 2006, 27:458-460.
50. Zhou P, Qian L, Chou T, Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis 2008, 29:543-551. 10.1016/j.nbd.2007.11.010, 2276562, 18178094.
51. McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K. Neuroprotective function of PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004, 24:257-268. 10.1523/JNEUROSCI.4485-03.2004, 14715958.
52. Ahmad AS, Zhuang H, Echeveriia V, Dore S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 2006, 23:1895-1903. 10.1089/neu.2006.23.1895, 17184197.
53. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Dore S. Prostagland EP4 receptor agonist protects against acute neurotoxicity. Brain Res 2005, 1066:71-77. 10.1016/j.brainres.2005.10.068, 16360658.
54. Xiang Z, Lin T, Reeves SA. 15d-PGJ2 induces apoptosis of mouse oligodendrocyte precursor cells. J Neuroinflammation 2007, 4:18. 10.1186/1742-2094-4-18, 1941731, 17634127.
55. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004, 351:1709-1711. 10.1056/NEJMp048288, 15470192.
56. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004, 351:1707-1709. 10.1056/NEJMp048286, 15470193.